Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to …
After a series of wins in heart failure, Eli Lilly and Boehringer Ingelheim are pumping the breaks on a late-stage Jardiance trial in chronic kidney …
Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s …
With drugmakers facing renewed calls to lower the cost of prescription drugs, Eli Lilly has taken preemptive action, dropping the cost of its generic insulin …
Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster …
The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results. AstraZeneca and Eli Lilly’s …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
